Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19.
COVID-19
Content validity
Patient experience
Patient-reported outcome
Signs and symptoms
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
29 Jul 2022
29 Jul 2022
Historique:
received:
14
12
2021
accepted:
25
05
2022
entrez:
29
7
2022
pubmed:
30
7
2022
medline:
30
7
2022
Statut:
epublish
Résumé
Given the urgent need for vaccines and treatments for coronavirus disease 2019 (COVID-19), the Symptoms of Infection with Coronavirus-19 (SIC), a comprehensive, patient-reported outcome (PRO) measure of signs and symptoms associated with COVID-19, was developed in full alignment with current US regulatory guidance to support evaluations of vaccines and treatments in development. An initial version of the SIC was developed to address concepts identified through a targeted literature review and consultation with experts in infectious diseases and clinicians routinely managing COVID-19 in a hospital setting. A qualitative study was conducted in sites in the United States among 31 participants aged ≥ 18 years who were English-speaking and willing and able to provide informed consent and a self-reported history by telephone or online method. The measure was refined based on additional feedback from the clinicians and three iterative rounds of combined concept elicitation and cognitive debriefing interviews conducted with patients, caregivers, and healthy volunteers. Among 39 scientific articles identified in the literature review, 35 COVID-19 signs and symptoms were reported and confirmed during interviews with clinicians, patients, and caregivers. Patients and healthy participants suggested changes for refining the draft SIC to ensure consistent interpretation and endorsed both the 24-h recall period and use of an 11-point numeric rating scale (NRS) for capturing change in symptom severity. The final version of the SIC captures the daily presence or absence of 30 symptoms and a rating of severity for 25 of the 30 symptoms using an NRS for those symptoms reported as present. The SIC comprehensively addresses observations described in the literature, by clinicians, and by patients, and captures patients' experiences with COVID-19 in a manner that minimizes complexity and facilitates completion for both patients and healthy volunteers. This measure is thus appropriate for use in clinical trials of both therapeutics and vaccines for COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Given the urgent need for vaccines and treatments for coronavirus disease 2019 (COVID-19), the Symptoms of Infection with Coronavirus-19 (SIC), a comprehensive, patient-reported outcome (PRO) measure of signs and symptoms associated with COVID-19, was developed in full alignment with current US regulatory guidance to support evaluations of vaccines and treatments in development.
METHODS
METHODS
An initial version of the SIC was developed to address concepts identified through a targeted literature review and consultation with experts in infectious diseases and clinicians routinely managing COVID-19 in a hospital setting. A qualitative study was conducted in sites in the United States among 31 participants aged ≥ 18 years who were English-speaking and willing and able to provide informed consent and a self-reported history by telephone or online method. The measure was refined based on additional feedback from the clinicians and three iterative rounds of combined concept elicitation and cognitive debriefing interviews conducted with patients, caregivers, and healthy volunteers.
RESULTS
RESULTS
Among 39 scientific articles identified in the literature review, 35 COVID-19 signs and symptoms were reported and confirmed during interviews with clinicians, patients, and caregivers. Patients and healthy participants suggested changes for refining the draft SIC to ensure consistent interpretation and endorsed both the 24-h recall period and use of an 11-point numeric rating scale (NRS) for capturing change in symptom severity. The final version of the SIC captures the daily presence or absence of 30 symptoms and a rating of severity for 25 of the 30 symptoms using an NRS for those symptoms reported as present.
CONCLUSIONS
CONCLUSIONS
The SIC comprehensively addresses observations described in the literature, by clinicians, and by patients, and captures patients' experiences with COVID-19 in a manner that minimizes complexity and facilitates completion for both patients and healthy volunteers. This measure is thus appropriate for use in clinical trials of both therapeutics and vaccines for COVID-19.
Identifiants
pubmed: 35904710
doi: 10.1186/s41687-022-00471-w
pii: 10.1186/s41687-022-00471-w
pmc: PMC9336135
doi:
Types de publication
Journal Article
Langues
eng
Pagination
85Informations de copyright
© 2022. The Author(s).
Références
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al (2020) A novel coronavirus from patients with pneumonia in China. N Engl J Med 382(8):727–733. https://doi.org/10.1056/NEJMoa2001017
doi: 10.1056/NEJMoa2001017
pubmed: 31978945
pmcid: 7092803
World Health Organization (2020) WHO Coronavirus Disease (COVID-19) Dashboard 2020. https://covid19.who.int/ . Accessed 11 Dec 2020
Jordan RE, Adab P, Cheng KK (2020) Covid-19: risk factors for severe disease and death. BMJ 368:m1198. https://doi.org/10.1136/bmj.m1198
doi: 10.1136/bmj.m1198
pubmed: 32217618
Centers for Disease Control and Prevention (CDC) (2020) Coronavirus (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/index.html . Accessed 11 Dec 2020
Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T et al (2020) Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect 80(6):656–665. https://doi.org/10.1016/j.jinf.2020.03.041
doi: 10.1016/j.jinf.2020.03.041
pubmed: 32283155
pmcid: 7151416
Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB et al (2020) COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 92(6):577–583. https://doi.org/10.1002/jmv.25757
doi: 10.1002/jmv.25757
pubmed: 32162702
pmcid: 7228329
Menni C, Sudre CH, Steves CJ, Ourselin S, Spector TD (2020) Quantifying additional COVID-19 symptoms will save lives. Lancet 395(10241):e107–e108. https://doi.org/10.1016/S0140-6736(20)31281-2
doi: 10.1016/S0140-6736(20)31281-2
pubmed: 32505221
pmcid: 7272184
Fernandez RS, Crivelli L, Guimet NM, Allegri RF, Pedreira ME (2020) Psychological distress associated with COVID-19 quarantine: latent profile analysis, outcome prediction and mediation analysis. J Affect Disord 277:75–84. https://doi.org/10.1016/j.jad.2020.07.133
doi: 10.1016/j.jad.2020.07.133
pubmed: 32799107
pmcid: 7413121
Huertas A, Montani D, Savale L, Pichon J, Tu L, Parent F et al (2020) Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur Respir J 56(1):66. https://doi.org/10.1183/13993003.01634-2020
doi: 10.1183/13993003.01634-2020
Johnson KD, Harris C, Cain JK, Hummer C, Goyal H, Perisetti A (2020) Pulmonary and extra-pulmonary clinical manifestations of COVID-19. Front Med 7:526. https://doi.org/10.3389/fmed.2020.00526
doi: 10.3389/fmed.2020.00526
Verstrepen K, Baisier L, De Cauwer H (2020) Neurological manifestations of COVID-19, SARS and MERS. Acta Neurol Belg 120(5):1051–1060. https://doi.org/10.1007/s13760-020-01412-4
doi: 10.1007/s13760-020-01412-4
pubmed: 32562214
pmcid: 7303437
Perisetti A, Gajendran M, Mann R, Elhanafi S, Goyal H (2020) COVID-19 extrapulmonary illness—special gastrointestinal and hepatic considerations. Dis Mon 66(9):101064. https://doi.org/10.1016/j.disamonth.2020.101064
doi: 10.1016/j.disamonth.2020.101064
pubmed: 32807535
pmcid: 7386425
Wise J (2020) COVID-19: study reveals six clusters of symptoms that could be used as a clinical prediction tool. BMJ 370:m2911. https://doi.org/10.1136/bmj.m2911
doi: 10.1136/bmj.m2911
pubmed: 32690476
Calvert M, Kyte D, Price G, Valderas JM, Hjollund NH (2019) Maximising the impact of patient reported outcome assessment for patients and society. BMJ 364:k5267. https://doi.org/10.1136/bmj.k5267
doi: 10.1136/bmj.k5267
pubmed: 30679170
Food and Drug Administration (FDA) (2020) Assessing COVID-19-related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment guidance for industry. https://www.fda.gov/media/142143/download . Accessed 11 Dec 2020
Aiyegbusi OL, Calvert MJ (2020) Patient-reported outcomes: central to the management of COVID-19. Lancet 396(10250):531. https://doi.org/10.1016/S0140-6736(20)31724-4
doi: 10.1016/S0140-6736(20)31724-4
pubmed: 32791038
pmcid: 7417142
Bastiani L, Fortunato L, Pieroni S, Bianchi F, Adorni F, Prinelli F et al (2021) Rapid COVID-19 screening based on self-reported symptoms: psychometric assessment and validation of the EPICOVID19 short diagnostic scale. J Med Internet Res 23(1):e23897. https://doi.org/10.2196/23897
doi: 10.2196/23897
pubmed: 33320825
pmcid: 7790735
Canas LS, Sudre CH, Capdevila Pujol J, Polidori L, Murray B, Molteni E et al (2021) Early detection of COVID-19 in the UK using self-reported symptoms: a large-scale, prospective, epidemiological surveillance study. Lancet Digit Health 3(9):e587–e598. https://doi.org/10.1016/S2589-7500(21)00131-X
doi: 10.1016/S2589-7500(21)00131-X
pubmed: 34334333
pmcid: 8321433
Richard SA, Epsi NJ, Pollett S, Lindholm DA, Malloy AMW, Maves R et al (2021) Performance of the inFLUenza patient-reported outcome plus (FLU-PRO Plus) instrument in patients with Coronavirus disease 2019. Open Forum Infect Dis 8(12):ofab517. https://doi.org/10.1093/ofid/ofab517
doi: 10.1093/ofid/ofab517
pubmed: 34901299
pmcid: 8661080
Centers for Disease Control and Prevention (CDC) (2021) Coronavirus self-checker. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/coronavirus-self-checker.html . Accessed 22 Sept 2021
Food and Drug Administration (FDA) (2009) Patient-reported outcome measures: use in medical product development to support labeling claims: guidance for industry. https://www.fda.gov/media/77832/download . Accessed 11 Dec 2020
Food and Drug Administration (FDA) (2017) Plan for issuance of patient-focused drug development guidance. https://www.fda.gov/media/105979/download . Accessed 11 Dec 2020
Food and Drug Administration (FDA) (2020) FDA patient-focused drug development guidance series for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making. https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical . Accessed 11 Dec 2020
European Medicines Agency (EMA) (2005) Reflection paper on the regulatory guidance for the use of healthrelated quality of life measures in the evaluation of medicinal products. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf . Accessed 11 Dec 2020
Heightman M, Prashar J, Hillman TE, Marks M, Livingston R, Ridsdale HA et al (2021) Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. BMJ Open Respir Res. https://doi.org/10.1136/bmjresp-2021-001041
doi: 10.1136/bmjresp-2021-001041
pubmed: 34764200
pmcid: 8587466
Evans RA, McAuley H, Harrison EM, Shikotra A, Singapuri A, Sereno M et al (2021) Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med 9(11):1275–1287. https://doi.org/10.1016/S2213-2600(21)00383-0
doi: 10.1016/S2213-2600(21)00383-0
pubmed: 34627560
pmcid: 8497028
Bargon CA, Batenburg MCT, van Stam LE, Mink van der Molen DR, van Dam IE, van der Leij F et al (2021) Impact of the COVID-19 pandemic on patient-reported outcomes of breast cancer patients and survivors. JNCI Cancer Spectr 5(1):pkaa104. https://doi.org/10.1093/jncics/pkaa104
doi: 10.1093/jncics/pkaa104
pubmed: 33437925
Tuttolomondo D, Frizzelli A, Aiello M, Bertorelli G, Majori M, Chetta A (2020) Beyond the lung involvement in COVID-19 patients. A review. Minerva Med. https://doi.org/10.23736/S0026-4806.20.06719-1
doi: 10.23736/S0026-4806.20.06719-1
pubmed: 32567823
Boeije HA (2002) A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant 36:391–409
doi: 10.1023/A:1020909529486
Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A et al (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21(7):839–842. https://doi.org/10.1016/j.jval.2017.11.014
doi: 10.1016/j.jval.2017.11.014
pubmed: 30005756
Magesh S, John D, Li WT, Li Y, Mattingly-App A, Jain S et al (2021) Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open 4(11):e2134147. https://doi.org/10.1001/jamanetworkopen.2021.34147
doi: 10.1001/jamanetworkopen.2021.34147
pubmed: 34762110
pmcid: 8586903
Romano C, Mayorga M, Fehnel S, Stoddard J, Sadoff J, Lewis S et al (2021) Qualitative interviews from a cross-sectional study to support the content validity of a patient-reported outcome measure of COVID-19 signs and symptoms in adults. Presented at: the European Scientific Working Group on Influenza (ESWI) Eighth Influenza Conference; December 5, 2021; Salzburg, Austria
Yelin D, Wirtheim E, Vetter P, Kalil AC, Bruchfeld J, Runold M et al (2020) Long-term consequences of COVID-19: research needs. Lancet Infect Dis 20(10):1115–1117. https://doi.org/10.1016/S1473-3099(20)30701-5
doi: 10.1016/S1473-3099(20)30701-5
pubmed: 32888409
pmcid: 7462626
Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC et al (2020) Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020. MMWR Morb Mortal Wkly Rep 69(30):993–998. https://doi.org/10.15585/mmwr.mm6930e1
doi: 10.15585/mmwr.mm6930e1
pubmed: 32730238
pmcid: 7392393
Salomon JA, Reinhart A, Bilinski A, Chua EJ, LaMotte-Kerr W, Ronn MM et al (2021) The US COVID-19 trends and impact survey: continuous real-time measurement of COVID-19 symptoms, risks, protective behaviors, testing, and vaccination. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.2111454118
doi: 10.1073/pnas.2111454118
pubmed: 34903656
pmcid: 8713763
Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B et al (2022) Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med. https://doi.org/10.1056/NEJMoa2117608
doi: 10.1056/NEJMoa2117608
pubmed: 35139271
pmcid: 8849184
Hardt K, Vandebosch A, Sadoff J, Gars ML, Truyers C, Lowson D et al (2022) Efficacy and safety of a booster regimen of Ad26.COV2.S vaccine against COVID-19. medRxiv:2022.2001.2028.22270043. https://doi.org/10.1101/2022.01.28.22270043 .